Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424183 · ClinicalTrials.gov registry record · Phase 2
T4/T3 Therapy in Hypothyroidism
A Phase 2 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07424183: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT07424183 is a Phase 2 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07424183, a Phase 2 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will test whether 6 months of combination therapy with levothyroxine (LT4) plus liothyronine (LT3) is superior to LT4 plus placebo in participants with hypothyroidism who have residual symptoms of hypothyroidism with TSH levels within the reference range.
Interventions
- DRUG Levothyroxine Sodium (LT4) Tablets
- DRUG Liothyronine (L-T3)
- DRUG Liothyronine (LT3) placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07424183
The ClinicalTrials.gov registry entry for NCT07424183 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Levothyroxine Sodium (LT4) Tablets is the first listed.
NCT07424183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07424183 about?
NCT07424183 is a clinical study titled "T4/T3 Therapy in Hypothyroidism". This study will test whether 6 months of combination therapy with levothyroxine (LT4) plus liothyronine (LT3) is superior to LT4 plus placebo in participants with hypothyroidism who have residual symptoms of hypothyroidism with TSH levels within the reference range.
What is the current status of trial NCT07424183?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-06. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07424183?
The interventions under investigation include: Levothyroxine Sodium (LT4) Tablets (DRUG), Liothyronine (L-T3) (DRUG), Liothyronine (LT3) placebo (DRUG).
Who is sponsoring clinical trial NCT07424183?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.